Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13 USD | +6.47% | -18.44% | +42.86% |
Apr. 17 | North American Morning Briefing : Stock Futures -2- | DJ |
Apr. 16 | Oppenheimer Upgrades Avalo Therapeutics to Outperform From Perform, Price Target is $35 | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 13.44M |
---|---|---|---|---|---|
Net income 2024 * | -33M | Net income 2025 * | -36M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-13.4
x | P/E ratio 2025 * |
-12.6
x | Employees | 19 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 0% |
1 day | +6.47% | ||
1 week | -4.55% | ||
Current month | -40.23% | ||
1 month | +168.60% | ||
3 months | +192.79% | ||
6 months | -49.23% | ||
Current year | +42.86% |
Managers | Title | Age | Since |
---|---|---|---|
Garry Neil
CEO | Chief Executive Officer | 70 | 20-01-31 |
Director of Finance/CFO | 40 | 17-12-31 | |
Dino Miano
COO | Chief Operating Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
June Almenoff
BRD | Director/Board Member | 67 | 21-11-09 |
Gilla Kaplan
BRD | Director/Board Member | 76 | 20-10-11 |
Garry Neil
CEO | Chief Executive Officer | 70 | 20-01-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-23 | 13 | +6.47% | 73,477 |
24-04-22 | 12.21 | +4.99% | 83,471 |
24-04-19 | 11.63 | -3.16% | 68,217 |
24-04-18 | 12.01 | -11.82% | 107,494 |
24-04-17 | 13.62 | -14.55% | 132,725 |
Delayed Quote Nasdaq, April 23, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+42.86% | 12.63M | |
+3.13% | 42.11B | |
+48.83% | 40.08B | |
+8.49% | 40B | |
-10.82% | 26.87B | |
+8.26% | 24.58B | |
-23.69% | 18.44B | |
+1.58% | 11.94B | |
+32.83% | 11.66B | |
+6.63% | 11.01B |
- Stock Market
- Equities
- AVTX Stock